Multiple studies have identified predictive biomarkers for therapy response that include activity of intratumor immunological effector cells (Riaz et al., 2017; Yuan et al., 2011), tumor mutational burden (Riaz et al., 2017; Van Allen et al., 2015), mismatch repair deficiency (Le et al., 2017b; Viale et al., 2017), tumor aneuploidy (Davoli et al., 2017), PDL1 levels (Long et al., 2016; Patel and Kurzrock, 2015), and intestinal microbiota (Gopalakrishnan et al., 2018; Matson et al., 2018). Here, CD274 is linked to neoplasm.